Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer

Malte Rieken, Luis A. Kluth, Evanguelos Xylinas, Harun Fajkovic, Andreas Becker, Pierre I. Karakiewicz, Michael Herman, Yair Lotan, Christian Seitz, Paul Schramek, Mesut Remzi, Wolfgang Loidl, Karl Pummer, Richard K. Lee, Talia Faison, Douglas S. Scherr, Alexandra Kautzky-Willer, Alexander Bachmann, Ashutosh Tewari, Shahrokh F. Shariat

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial. Methods: We retrospectively evaluated 6,863 patients who underwent RP for clinically localized PC between 2000 and 2011. Univariable and multivariable Cox regression models addressed the association of DM and metformin use with BCR. Results: Overall, 664 patients had a diagnosis of DM from which 287 (43 %) were on metformin and 377 (57 %) were on anti-diabetics other than metformin. DM and metformin were not associated with any clinicopathologic features (p values >0.05). Within a median follow-up of 25 months (interquartile range 35 months), 774 (11.3 %) patients experienced BCR. Actuarial 5-year biochemical-free survival was 83 % for non-diabetic, 79 % for diabetic patients without metformin use, and 85 % for diabetic patients with metformin use (log rank p = 0.17). In uni- and multivariable Cox regression analyses with the non-diabetic group as referent, DM without metformin use (HR = 0.99; 95 % CI 0.75-1.30, p = 0.65) and DM with metformin use (HR = 0.84, 95 % CI 0.58-1.22, p = 0.36) were not associated with BCR after RP. A subgroup analysis stratified by nodal status, surgical margins, tumor stage, and Gleason sum did not reveal any significant association between DM, use of metformin and risk of BCR. Conclusions: We found no association between DM or metformin use and cancer-specific features or BCR in patients treated with RP. The effect of DM and metformin on complications, wound healing and overall survival needs to be assessed in similar cohorts.

Original languageEnglish (US)
Pages (from-to)999-1005
Number of pages7
JournalWorld Journal of Urology
Volume32
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Metformin
Prostatectomy
Prostatic Neoplasms
Diabetes Mellitus
Recurrence
Survival
Proportional Hazards Models
Wound Healing
Neoplasms
Regression Analysis

Keywords

  • Biochemical recurrence
  • Diabetes mellitus
  • Metformin
  • Prostate cancer
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. / Rieken, Malte; Kluth, Luis A.; Xylinas, Evanguelos; Fajkovic, Harun; Becker, Andreas; Karakiewicz, Pierre I.; Herman, Michael; Lotan, Yair; Seitz, Christian; Schramek, Paul; Remzi, Mesut; Loidl, Wolfgang; Pummer, Karl; Lee, Richard K.; Faison, Talia; Scherr, Douglas S.; Kautzky-Willer, Alexandra; Bachmann, Alexander; Tewari, Ashutosh; Shariat, Shahrokh F.

In: World Journal of Urology, Vol. 32, No. 4, 2014, p. 999-1005.

Research output: Contribution to journalArticle

Rieken, M, Kluth, LA, Xylinas, E, Fajkovic, H, Becker, A, Karakiewicz, PI, Herman, M, Lotan, Y, Seitz, C, Schramek, P, Remzi, M, Loidl, W, Pummer, K, Lee, RK, Faison, T, Scherr, DS, Kautzky-Willer, A, Bachmann, A, Tewari, A & Shariat, SF 2014, 'Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer', World Journal of Urology, vol. 32, no. 4, pp. 999-1005. https://doi.org/10.1007/s00345-013-1171-7
Rieken, Malte ; Kluth, Luis A. ; Xylinas, Evanguelos ; Fajkovic, Harun ; Becker, Andreas ; Karakiewicz, Pierre I. ; Herman, Michael ; Lotan, Yair ; Seitz, Christian ; Schramek, Paul ; Remzi, Mesut ; Loidl, Wolfgang ; Pummer, Karl ; Lee, Richard K. ; Faison, Talia ; Scherr, Douglas S. ; Kautzky-Willer, Alexandra ; Bachmann, Alexander ; Tewari, Ashutosh ; Shariat, Shahrokh F. / Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. In: World Journal of Urology. 2014 ; Vol. 32, No. 4. pp. 999-1005.
@article{04cd0b6dcca6495a94490bd2d27cf22e,
title = "Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer",
abstract = "Purpose: The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial. Methods: We retrospectively evaluated 6,863 patients who underwent RP for clinically localized PC between 2000 and 2011. Univariable and multivariable Cox regression models addressed the association of DM and metformin use with BCR. Results: Overall, 664 patients had a diagnosis of DM from which 287 (43 {\%}) were on metformin and 377 (57 {\%}) were on anti-diabetics other than metformin. DM and metformin were not associated with any clinicopathologic features (p values >0.05). Within a median follow-up of 25 months (interquartile range 35 months), 774 (11.3 {\%}) patients experienced BCR. Actuarial 5-year biochemical-free survival was 83 {\%} for non-diabetic, 79 {\%} for diabetic patients without metformin use, and 85 {\%} for diabetic patients with metformin use (log rank p = 0.17). In uni- and multivariable Cox regression analyses with the non-diabetic group as referent, DM without metformin use (HR = 0.99; 95 {\%} CI 0.75-1.30, p = 0.65) and DM with metformin use (HR = 0.84, 95 {\%} CI 0.58-1.22, p = 0.36) were not associated with BCR after RP. A subgroup analysis stratified by nodal status, surgical margins, tumor stage, and Gleason sum did not reveal any significant association between DM, use of metformin and risk of BCR. Conclusions: We found no association between DM or metformin use and cancer-specific features or BCR in patients treated with RP. The effect of DM and metformin on complications, wound healing and overall survival needs to be assessed in similar cohorts.",
keywords = "Biochemical recurrence, Diabetes mellitus, Metformin, Prostate cancer, Radical prostatectomy",
author = "Malte Rieken and Kluth, {Luis A.} and Evanguelos Xylinas and Harun Fajkovic and Andreas Becker and Karakiewicz, {Pierre I.} and Michael Herman and Yair Lotan and Christian Seitz and Paul Schramek and Mesut Remzi and Wolfgang Loidl and Karl Pummer and Lee, {Richard K.} and Talia Faison and Scherr, {Douglas S.} and Alexandra Kautzky-Willer and Alexander Bachmann and Ashutosh Tewari and Shariat, {Shahrokh F.}",
year = "2014",
doi = "10.1007/s00345-013-1171-7",
language = "English (US)",
volume = "32",
pages = "999--1005",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer

AU - Rieken, Malte

AU - Kluth, Luis A.

AU - Xylinas, Evanguelos

AU - Fajkovic, Harun

AU - Becker, Andreas

AU - Karakiewicz, Pierre I.

AU - Herman, Michael

AU - Lotan, Yair

AU - Seitz, Christian

AU - Schramek, Paul

AU - Remzi, Mesut

AU - Loidl, Wolfgang

AU - Pummer, Karl

AU - Lee, Richard K.

AU - Faison, Talia

AU - Scherr, Douglas S.

AU - Kautzky-Willer, Alexandra

AU - Bachmann, Alexander

AU - Tewari, Ashutosh

AU - Shariat, Shahrokh F.

PY - 2014

Y1 - 2014

N2 - Purpose: The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial. Methods: We retrospectively evaluated 6,863 patients who underwent RP for clinically localized PC between 2000 and 2011. Univariable and multivariable Cox regression models addressed the association of DM and metformin use with BCR. Results: Overall, 664 patients had a diagnosis of DM from which 287 (43 %) were on metformin and 377 (57 %) were on anti-diabetics other than metformin. DM and metformin were not associated with any clinicopathologic features (p values >0.05). Within a median follow-up of 25 months (interquartile range 35 months), 774 (11.3 %) patients experienced BCR. Actuarial 5-year biochemical-free survival was 83 % for non-diabetic, 79 % for diabetic patients without metformin use, and 85 % for diabetic patients with metformin use (log rank p = 0.17). In uni- and multivariable Cox regression analyses with the non-diabetic group as referent, DM without metformin use (HR = 0.99; 95 % CI 0.75-1.30, p = 0.65) and DM with metformin use (HR = 0.84, 95 % CI 0.58-1.22, p = 0.36) were not associated with BCR after RP. A subgroup analysis stratified by nodal status, surgical margins, tumor stage, and Gleason sum did not reveal any significant association between DM, use of metformin and risk of BCR. Conclusions: We found no association between DM or metformin use and cancer-specific features or BCR in patients treated with RP. The effect of DM and metformin on complications, wound healing and overall survival needs to be assessed in similar cohorts.

AB - Purpose: The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial. Methods: We retrospectively evaluated 6,863 patients who underwent RP for clinically localized PC between 2000 and 2011. Univariable and multivariable Cox regression models addressed the association of DM and metformin use with BCR. Results: Overall, 664 patients had a diagnosis of DM from which 287 (43 %) were on metformin and 377 (57 %) were on anti-diabetics other than metformin. DM and metformin were not associated with any clinicopathologic features (p values >0.05). Within a median follow-up of 25 months (interquartile range 35 months), 774 (11.3 %) patients experienced BCR. Actuarial 5-year biochemical-free survival was 83 % for non-diabetic, 79 % for diabetic patients without metformin use, and 85 % for diabetic patients with metformin use (log rank p = 0.17). In uni- and multivariable Cox regression analyses with the non-diabetic group as referent, DM without metformin use (HR = 0.99; 95 % CI 0.75-1.30, p = 0.65) and DM with metformin use (HR = 0.84, 95 % CI 0.58-1.22, p = 0.36) were not associated with BCR after RP. A subgroup analysis stratified by nodal status, surgical margins, tumor stage, and Gleason sum did not reveal any significant association between DM, use of metformin and risk of BCR. Conclusions: We found no association between DM or metformin use and cancer-specific features or BCR in patients treated with RP. The effect of DM and metformin on complications, wound healing and overall survival needs to be assessed in similar cohorts.

KW - Biochemical recurrence

KW - Diabetes mellitus

KW - Metformin

KW - Prostate cancer

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84904874670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904874670&partnerID=8YFLogxK

U2 - 10.1007/s00345-013-1171-7

DO - 10.1007/s00345-013-1171-7

M3 - Article

C2 - 24062093

AN - SCOPUS:84904874670

VL - 32

SP - 999

EP - 1005

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 4

ER -